Sox2 promotes tamoxifen resistance in breast cancer cells [PDF]
EMBO Molecular Medicine, 2013 Development of resistance to therapy continues to be a serious clinical problem in breast cancer management. Cancer stem/progenitor cells have been shown to play roles in resistance to chemo‐ and radiotherapy.
Marco Piva +10 more
doaj +7 more sources
PARP14-mediated glycolysis enhances Tamoxifen resistance in estrogen receptor + breast cancer cells [PDF]
Discover OncologyBackground Resistance to Tamoxifen is a major challenge in the therapeutic management of estrogen receptor (ER) + breast cancer (BC). Glycolysis, as reported, exerts a crucial influence on the regulation of Tamoxifen resistance in BC, highlighting the ...
Wenju Mo +4 more
doaj +2 more sources
Response Gene to Complement 32 promotes cell proliferation and tamoxifen resistance in breast cancer via elevated FoxM1 expression. [PDF]
PLoS ONEDespite the high sensitivity of estrogen receptor positive (ER+) breast cancer to endocrine therapy, many patients have primary resistance or develop resistance to endocrine therapies.
Xinlei Li +6 more
doaj +2 more sources
Cancer-associated fibroblast promotes tamoxifen resistance in estrogen receptor positive breast cancer via exosomal LncRNA PRKCQ-AS1/miR-200a-3p/MKP1 axis-mediated apoptosis suppression [PDF]
Journal of Experimental & Clinical Cancer ResearchBackground Tamoxifen resistance remains a significant challenge in the endocrine therapy of estrogen receptor-positive (ER+) breast cancer. Cancer-associated fibroblasts (CAFs) facilitate therapeutic resistance through exosome secretion, yet the role of ...
Chenghui Wu +14 more
doaj +2 more sources
MIR497HG‐Derived miR‐195 and miR‐497 Mediate Tamoxifen Resistance via PI3K/AKT Signaling in Breast Cancer [PDF]
Advanced Science, 2023 Tamoxifen is commonly used for the treatment of patients with estrogen receptor‐positive (ER+) breast cancer, but the acquired resistance to tamoxifen presents a critical challenge of breast cancer therapeutics.
Yao Tian +9 more
doaj +2 more sources
LINC00626 drives tamoxifen resistance in breast cancer cells by interaction with UPF1 [PDF]
Scientific ReportsAlthough tamoxifen is commonly utilized as adjuvant therapy for Estrogen Receptor alpha (ERα)-positive breast cancer patients, approximately 30–50% of individuals treated with tamoxifen experience relapse.
Hui Yuan +3 more
doaj +2 more sources
Overexpression of COL11A1 confers tamoxifen resistance in breast cancer [PDF]
npj Breast CancerBreast cancer is the most commonly diagnosed malignancy and benefits from endocrine agents such as tamoxifen. However, the development of drug resistance in cancerous cells often leads to recurrence, thus limiting the therapeutic benefit.
Chengxiao Fu +4 more
doaj +2 more sources
Frontiers in Oncology, 2022 Acquired resistance is a major clinical challenge for tamoxifen-based therapy. In this study, we focused on lncRNA SNHG6 which plays a role in chemoresistance of cancer cells, but has never been investigated in the context of tamoxifen resistance.
Mohammad Imran Khan +2 more
doaj +1 more source
NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer
Cells, 2021 Endocrine therapy is used to treat estrogen receptor (ER)-positive breast cancer. Tamoxifen is effective against this cancer subtype. Nonetheless, approximately 30% of patients treated with tamoxifen acquire resistance, resulting in therapeutic ...
Yu Cheon Kim +3 more
doaj +1 more source
Molecular Therapy: Oncolytics, 2020 Endocrine therapy is a systemic therapy and has become the main treatment strategy for patients with estrogen receptor (ER)-positive breast cancer.
Jun Zhou +9 more
doaj +1 more source